Telix Pharmaceuticals Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TLX Nasdaq 2830 telixpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Telix Pharmaceuticals Limited

Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect? - Jul 22nd, 2026 7:55 am
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal - Jul 21st, 2026 3:00 pm
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress - Jul 20th, 2026 5:31 pm
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer - Jul 20th, 2026 3:00 pm
Telix Completes Patient Enrollment in TLX591-Px (Illuccix®) Japan Phase 3 Study - Jul 16th, 2026 4:00 pm
Telix opens radiopharmaceutical facility in Australia for cancer treatment - Jul 16th, 2026 4:12 am
Telix Opens Australian-First Facility to Accelerate Delivery of New Cancer Treatments and Expand Sovereign Manufacturing - Jul 15th, 2026 6:30 pm
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer - Jul 15th, 2026 2:30 pm
FDA Alignment to Advance ProstACT Global Phase 3 Trial - Jul 1st, 2026 7:31 pm
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions - Jun 22nd, 2026 3:40 pm
Telix Pharmaceuticals (TLX), United Imaging Healthcare Form Strategic Theranostics Research Partnership - Jun 17th, 2026 1:38 pm
ASX Growth Companies With Insider Ownership Up To 20% - Jun 4th, 2026 1:38 pm
Telix and United Imaging Announce Strategic Theranostics Collaboration - Jun 2nd, 2026 5:00 am
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026 - Jun 1st, 2026 3:00 pm
Is Telix (ASX:TLX) Quietly Assembling a Connected Oncology Platform That Reshapes Its Moat? - May 28th, 2026 3:10 pm
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences - May 27th, 2026 5:00 am
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing - May 18th, 2026 3:00 pm
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - May 15th, 2026 4:30 am
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC - May 4th, 2026 3:00 pm
Insider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of Shares - May 1st, 2026 2:50 pm